Chemotherapy for advanced and/or recurrent cervical cancer.
A combination of bleomycin, vincristine, mitomycin-C, and cisplatin was used to treat 39 patients with advanced and/or recurrent cervical cancer. Twenty patients showed an objective response (complete or partial) with a mean duration of 14.8 months. The overall response rate was 58.8%. Twelve patients are still alive and in remission 7-36 months after the start of chemotherapy. Toxicity was acceptable.
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage*; D009362:Neoplasm Metastasis; D013997:Time Factors; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000401:mortality; D014750:Vincristine / Q000008:administration & dosage*
D008937:Mitomycins; D001761:Bleomycin; D016685:Mitomycin; D014750:Vincristine; D002945:Cisplatin